Investment Rating - The report maintains a "Recommended" rating for the company [2][4]. Core Viewpoints - The company is deeply engaged in the chain rehabilitation medical industry, showing stable internal growth and accelerated external expansion, with the rehabilitation segment expected to develop rapidly against the backdrop of an aging population [2]. - The intelligent power distribution segment is experiencing steady growth domestically, while overseas operations are gradually breaking through, becoming the second growth point for the segment [2]. - Revenue forecasts for 2025-2027 are projected at 177.02 billion, 211.02 billion, and 249.68 billion yuan, with year-on-year growth rates of 21.2%, 19.2%, and 18.3% respectively [2][3]. - Net profit forecasts for the same period are 27.75 billion, 33.67 billion, and 40.17 billion yuan, with growth rates of 22.8%, 21.3%, and 19.3% respectively [2][3]. Financial Performance Summary - In 2024, the company achieved a revenue of 14.6 billion yuan, a year-on-year increase of 27.38%, and a net profit of 2.26 billion yuan, up 18.69% year-on-year [1][3]. - The gross profit margin for 2024 was 34.72%, an increase of 0.73 percentage points year-on-year [1]. - The medical services segment generated revenue of 3.26 billion yuan, with a gross margin of 34.30%, while the intelligent power distribution segment achieved revenue of 11.12 billion yuan with a gross margin of 34.81% [1]. - Domestic revenue reached 11.67 billion yuan, up 25.49% year-on-year, while overseas revenue was 2.71 billion yuan, up 38.40% year-on-year [1]. Business Segmentation Insights - The intelligent power distribution business has a strong order backlog, with total orders amounting to 13.202 billion yuan, a year-on-year increase of 25.81% [6]. - The medical services business is steadily growing, with the company expanding its rehabilitation service network, adding 10 new hospitals, and increasing its total hospital count to 38 [6].